Abstract
Intraprocedural stent thrombosis (IPST), defined as the development of occlusive or nonocclusive new thrombus in or adjacent to a recently implanted stent before completion of PCI. IPST even though a rare entity, yet is associated with worse prognosis amongst all intraprocedural thrombotic events.
Data regarding the impact of IPST is scarce and needs further investigation.
We performed literature search of all published full-length articles that studied and compared data on patients with IPST and with no IPST during PCI. We calculated odds ratios via the random effects model for 30 day and 1 year outcomes.
Our literature search yielded 3 studies (1 retrospective, 2 observational post-hoc analysis) relevant to the meta-analysis. Total 19272 patients were included. IPST occurred in 159 patients (0.8%). At 30 days, IPST was associated with statistically significant higher all-cause mortality (OR 10.79, 95% CI [6.31, 18.45] p<0.00001), MI (OR 4.82, 95% CI [2.39, 9.73] p<0.0001), target vessel revascularization (TVR) (OR 6.70, 95% CI [3.38, 13.29] p<0.00001), definite stent thrombosis (OR 10.44, 95% CI [5.87, 18.58] p<0.00001), definite or probable stent thrombosis (OR 9.28), 95% CI [5.54, 15.56] p<0.00001) and death or MI or TVR (OR 7.20], 95% CI [4.10, 12.64] p<0.00001), than those without IPST. At one year, results remained statistically significant for higher mortality (OR 4.27, 95% CI [1.92, 9.49] p=0.0004) and death or MI or TVR (OR 2.91, 95% CI [1.58, 5.36] p=0.0006) in patients with IPST.
IPST even though is a rare occurrence, is associated with more adverse ischemic events, including higher mortality at 30 days and 1 year.
Type of funding source: None
